Who is affected by this change?

This affects Independence Blue Cross Neurology, Pediatrics providers on Commercial plans.

When does this change take effect?

This change is effective Jul 23, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.02.13a, Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; Elevidys®)

Independence Blue Cross·Neurology, Pediatrics·Pharmacy

Effective date

Jul 23, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

IBX has reissued policy 08.02.13a for Delandistrogene moxeparvovec (Elevidys®), a gene therapy drug. This is a pharmacy policy update with a future effective date of July 23, 2025.

Action Required

Action needed

By July 23, 2025: Review updated IBX policy for Elevidys® gene therapy coverage requirements. Billing team should access the full policy details at the provided URL to understand any changes to prior authorization, coverage criteria, or billing requirements for this specialty drug.

Related policy hubs

Independence Blue Cross policies Neurology Pediatrics